Prevalence and Correlation of Depression in Patients Suffering From Type 2 diabetes Mellitus

Abstract

Depression is one of the commonest psychiatric disorders and is a prominent reason for major health problems worldwide. The prevalence and the dysfunction, morbidity, suffering, and economic burden. Depression can lead to upsurge in the health-seeking performance, diminished excellence of life and increased propensity for desperate tendencies. In the majority of the cases, the affected patients report late and owing to various scales of assessing depression, patients with depressive disorder are often undertreated. As per the Global Burden of Disease report the prevalence of depression is 1.9% among men and 3.2% for women and the overall one-year prevalence increases to 5.8% in men and 9.5% in women. Given the existing epidemiological evolution and demographic, the impact of unhappiness can be tremendous by 2020 with the burden of depression at about 5.7% of all the illnesses. The morbidity bearing will be so huge that and it would be the most important reason for disability-adjusted life years (DALYs), next only to ischemic heart disease. This education expected at to assess the prevalence and correlates of depression among type 2 diabetes mellitus patients and impact of treatment on diabetic status, glycemic quality and control of life after 6 months. The scales used in this study was Mini international neuropsychiatric interview – 6.0 , Hamilton Depression Scale (HAM-D), WHO Quality Of Life (WHO-QOL) – BREF scales, Morisky 8-item Medication Adherence Questionnaire. The study has highlighted the prevalence of depression in the study population, positive impact of depression on the treatment compliance, glycemic control and quality of life of the affected patients.